Appl. No.: 10/666,689

Filed: September 19, 2003

Response to Office Action mailed on: April 6, 2007

## **Amendments to the Claims:**

This listing of claims will replace all prior versions and listing of claims in the application:

## Listing of claims:

1-19 (Cancelled).

20. (Previously presented) An isolated polypeptide comprising the amino acid sequence of Figure 5 (SEQ ID NO:6) having from 0 to 5 amino acid residues that are added, deleted or conservatively substituted.

21. (Previously presented) The polypeptide of Claim 20 comprising the amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that added.

22. (Previously presented) The polypeptide of Claim 20 comprising the amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that are deleted.

23. (Previously presented) The polypeptide of Claim 20 comprising the amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that are conservatively substituted.

24. (Previously presented) The polypeptide of Claim 20 comprising the amino acid sequence of Figure 5 (SEQ ID NO:6).

25. (Previously presented) An isolated polypeptide comprising an extracellular segment of Figure 5 (SEQ ID NO:6).

26. (Cancelled).

27. (Previously presented) The polypeptide of Claim 25, wherein the extracellular segment comprises the N-terminal fragment.

Appl. No.: 10/666,689

Filed: September 19, 2003

Response to Office Action mailed on: April 6, 2007

28. (Cancelled).

- 29. (Previously presented) A composition comprising the polypeptide of Claim 20 and a pharmaceutically acceptable carrier.
- 30. (Previously presented) A composition comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.
- 31 73 (Cancelled).